Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., . Helmick, C. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults – United States, 2016. MMWR Morb Mortal Wkly Rep, 67(36), 1001-1006. doi:10. 15585/mmwr. mm6736a2 Bruni, N., Della Pepa, C., Oliaro-Bosso, S., Pessione, E., Gastaldi, D., & Dosio, F.
Cannabinoid Delivery Systems for Pain and Inflammation Treatment. Molecules, 23(10). doi:10. 3390/molecules23102478 Xu, Q., & Yaksh, T. L. (2011). A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. Curr Opin Anaesthesiol, 24(4), 400-407. doi:10. 1097/ACO.0b013e32834871df Kidd, B. A., Wroblewska, A., Boland, M. R., Agudo, J., Merad, M., Tatonetti, N.
T. (2016). Mapping the effects of drugs on the immune system. Nature biotechnology, 34(1), 47. Xiong, W., Cui, T., Cheng, K., Yang, F., Chen, S. R., Willenbring, D., . Zhang, L. (2012). Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. J Exp Med, 209(6), 1121-1134. doi:10.
20120242 Meacham, K., Shepherd, A., Mohapatra, D. P., & Haroutounian, S. (2017). Neuropathic Pain: Central vs. Peripheral Mechanisms. Curr Pain Headache Rep, 21(6), 28. doi:10. 1007/s11916-017-0629-5 Rifbjerg-Madsen, S., Christensen, A. W., Christensen, R., Hetland, M. L., Bliddal, H., Kristensen, L. E., . Amris, K. (2017). Pain and pain mechanisms in patients with inflammatory arthritis: A Danish nationwide cross-sectional DANBIO registry survey.
doi:10. 1371/journal. pone.0180014 De Gregorio, D., McLaughlin, R. J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez-Canul, M., . Gobbi, G. (2019). Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain, 160(1), 136-150. doi:10. 1097/j. pain.0000000000001386 Adela Hilda Onuțu, D. S.
a. C. P. (2018). Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management. Retrieved from https://www. intechopen.com/books/serotonin/serotonin-reuptake-inhibitors-and-their-role-in-chronic-pain-management Ward, S. J., McAllister, S. D., Kawamura, R., Murase, R., Neelakantan, H., & Walker, E. A. (2014). Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.
doi:10. 1111/bph. 12439 Cunetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., & Orihuela, S. (2018). Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplant Proc, 50(2), 461-464. doi:10. 1016/j. transproceed.2017. 12.042 Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C.
Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 ‘N of 1’ studies. Anaesthesia, 59(5), 440-452. doi:10. 1111/j. 1365-2044. 2004.03674. x Libzon, S., Schleider, L. B., Saban, N., Levit, L., Tamari, Y., Linder, I., . Blumkin, L. (2018). Medical Cannabis for Pediatric Moderate to Severe Complex Motor Disorders.
doi:10. 1177/0883073818773028 Naftali, T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., . Konikoff, F. M. (2017). Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial. Dig Dis Sci, 62(6), 1615-1620. doi:10. 1007/s10620-017-4540-z MacCallum, C. A., & Russo, E.
CBD oil is a good, natural agent, which can help attenuate stress, insomnia and depressive symptoms. CBD possesses potent anti-anxiety property, which helps in alleviating general as well as social anxiety. Case studies have shown that CBD is helpful in providing relief from insomnia by improving the quality and quantity of sleep in users.
CBD alters these receptors in such a way that it results in an anxiolytic effect. CB1R receptors activation is known to be the target of anti-anxiety drugs. CBD is an indirect activator of this receptor via increased CB1R constitutional activity. CBD administration to mouse models of generalized anxiety showed that regular use of CBD for 21 days could reduce stress and has anxiolytic effects.
CBD is known to amplify the adenosine receptor activity, which in turn reduces anxiety. CBD helps reduce anxiety generated due to chronic unpredictable stress and thus prevents long-term anxiogenic effects of stress. Use of CBD in the treatment of sleep disorders has also been studied widely. A case study of a patient with insomnia (due to Posttraumatic stress disorder) showed that CBD intake could improve the quality of sleep.
Treatment of rats with CBD led to increased total sleep time in them at the high dose of 40mg/kg. CBD might increase total sleep time and sleep latency at higher doses. Stress, anxiety, depressive symptoms, and sleep disorders are common amongst patients with back pain. In order to improve the quality of life, it is important to alleviate these co-morbidities.
Muscle relaxants are another type of medication prescribed to the patients with back pain for treatment of painful musculoskeletal conditions. They are known to alleviate spasms or pain developed due to injury such as low back pain. CBD has muscle relaxant properties. It has been shown in studies that CBD and other components of cannabis have muscle relaxant properties.
CBD has been found to be instrumental in the treatment of multiple sclerosis by reducing muscle spasticity. CBD is known to influence the endocannabinoid system by altering the levels of many endogenous cannabinoids including anandamide. This, in turn, can result in the muscle relaxant properties of CBD. Muscle relaxants are a group of drugs prescribed to the patients with back pain.
The effective dose depends on many factors including the strength of the tincture, user’s condition, age, tolerance, etc. It has been observed that dose between 600mg-1500mg per day is fairly well tolerated in humans without many side effects. Dose above 1500mg per day might result in some side effects. Tinctures are usually available in 100mg to 600mg concentrations.
Users should start with low doses and then increase it gradually based on their symptoms. Taking extra oil is expensive and ineffective in the long run. Therefore the users can start with a 300mg dose and observe their symptoms. In case of relief, the dose can be reduced to 100mg.